Primary Site >> Colorectal Cancer
Gene >> KDR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. PMID: 8402650 |
Ref: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. PMID: 7535799 Ref: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. PMID: 7664263 |
Ref: Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. PMID: 9570376 |
Ref: Regulation of vascular endothelial growth factor receptor KDR in vitro by a soluble factor in confluent endothelial cells. PMID: 9732240 |
Ref: Increased expression of angiogenic factors in human colonic angiodysplasia. PMID: 10201485 Ref: A novel gene delivery system targeting cells expressing VEGF receptors. PMID: 10321685 Ref: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. PMID: 10554007 |
Ref: Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. PMID: 10738243 Ref: Factors influencing tissue concentration of vascular endothelial growth factor in colorectal carcinoma. PMID: 10763960 Ref: Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. PMID: 10804085 Ref: Angiogenesis of liver metastases: role of sinusoidal endothelial cells. PMID: 10910247 Ref: Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. PMID: 10931447 |
Ref: Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. PMID: 11172585 Ref: [Significance of angiogenesis and clinical application of anti-angiogenesis]. PMID: 11394000 Ref: Technology evaluation: IMC-1C11, ImClone Systems. PMID: 11525567 Ref: Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. PMID: 11562278 Ref: VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. PMID: 11687953 Ref: Expression of vascular endothelial growth factor and its receptor KDR (kinase domain-containing receptor)/Flk-1 (fetal liver kinase-1) as prognostic factors in human colorectal cancer. PMID: 11723743 Ref: VEGF antagonists. PMID: 11727506 |
Ref: Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. PMID: 11912138 Ref: Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen. PMID: 11973650 Ref: Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. PMID: 12168886 Ref: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. PMID: 12415261 |
Ref: A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. PMID: 12684400 Ref: Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. PMID: 12684431 Ref: The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. PMID: 12754739 Ref: Quantitative analysis of lymphangiogenic markers in human colorectal cancer. PMID: 12851706 Ref: CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. PMID: 14522925 |
Ref: In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. PMID: 14760097 Ref: Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. PMID: 14760102 Ref: Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. PMID: 14985702 Ref: Expression of vascular endothelial growth factor and receptor flk-1 in colon cancer liver metastases. PMID: 15235888 Ref: (125)I-Vascular endothelial growth factor-121 PMID: 20641207 Ref: (111)In-Diethylenetriamine pentaacetic acid-bevacizumab PMID: 20641545 Ref: Alexa Fluor 680-Bevacizumab PMID: 20641728 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-quantum dot-vascular endothelial growth factor PMID: 20641777 Ref: (89)Zr-N-Succinyldesferrioxamine-bevacizumab PMID: 20641842 Ref: (86)Y-CHX-A''-Diethylenetriamine pentaacetic acid-bevacizumab PMID: 21433411 Ref: Anti-vascular endothelial growth factor polylactic acid-polyethylene glycol-poly-L-Lys/gadolinium-diethylenetriamine pentaacetic acid nanoparticles PMID: 22812022 Ref: (64)Cu-1,4,7-Triazacyclononane-1,4,7-triacetic acid-p-isothiocyanatobenzyl-bevacizumab-IRDye 800CW PMID: 23534080 |
Ref: Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. PMID: 15705616 Ref: Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. PMID: 15735759 Ref: Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. PMID: 15743179 Ref: Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. PMID: 15743202 Ref: Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. PMID: 15867367 Ref: Molecularly targeted therapy for gastrointestinal cancer. PMID: 15892618 Ref: [Adenovirus-mediated CDglyTK fusion gene system driven by KDR promoter selectively kills colorectal cancer cells]. PMID: 15897124 Ref: Silibinin inhibits angiogenesis via Flt-1, but not KDR, receptor up-regulation. PMID: 15993897 Ref: Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells. PMID: 16015035 Ref: [Adenovirus mediated double suicide gene under controlling by KDR promoter selectively kills vascular endothelial cells and colorectal tumor cells]. PMID: 16155828 Ref: Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor. PMID: 16230386 Ref: [Therapeutic strategies using VEGF inhibitors in colorectal cancer]. PMID: 16387667 |
Ref: Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. PMID: 16114015 Ref: Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers. PMID: 16177881 Ref: Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. PMID: 16321517 Ref: Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells. PMID: 16618894 Ref: Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. PMID: 16688779 Ref: Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2. PMID: 16789733 Ref: The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. PMID: 16891460 Ref: Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. PMID: 16891475 Ref: Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts. PMID: 16928828 Ref: Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects. PMID: 16937523 Ref: Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers. PMID: 17096728 Ref: Radioiodinated VEGF to image tumor angiogenesis in a LS180 tumor xenograft model. PMID: 17127168 |
Ref: Absence of tyrosine kinase mutations in Japanese colorectal cancer patients. PMID: 17016444 Ref: Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. PMID: 17167497 Ref: Sunitinib: from rational design to clinical efficacy. PMID: 17327610 Ref: [Targeted killing of colorectal tumor cells by lentiviral constructs containing CD/TK suicide genes and KDR promoter]. PMID: 17545072 Ref: Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. PMID: 17638901 Ref: Underexpression of mineralocorticoid receptor in colorectal carcinomas and association with VEGFR-2 overexpression. PMID: 17703341 Ref: Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. PMID: 17883421 Ref: A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver. PMID: 17949968 Ref: New approaches in angiogenic targeting for colorectal cancer. PMID: 17990351 Ref: Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice. PMID: 18084614 Ref: Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. PMID: 18086000 |
Ref: Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. PMID: 18172321 Ref: [Specific killing effects of combination of recombinant adenovirus containing double suicide gene driven by KDR promoter and survivin antisense oligonucleotide on colorectal cancer cells and vascular endothelial cells]. PMID: 18197498 Ref: Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. PMID: 18206383 Ref: Messenger RNA expression of vascular endothelial growth factor and its receptors in primary colorectal cancer and corresponding liver metastasis. PMID: 18239970 Ref: Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines. PMID: 18292935 Ref: Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. PMID: 18324358 Ref: Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors. PMID: 18324759 Ref: Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice. PMID: 18347145 Ref: The effect of emodin on VEGF receptors in human colon cancer cells. PMID: 18454691 Ref: Hepatic ischemia-reperfusion increases vascular endothelial growth factor and cancer growth in rats. PMID: 18468635 Ref: Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. PMID: 18619649 Ref: Quantification of circulating endothelial and progenitor cells: comparison of quantitative PCR and four-channel flow cytometry. PMID: 18755033 Ref: Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells. PMID: 18790786 Ref: Antitumor activities of synthetic and natural stilbenes through antiangiogenic action. PMID: 19016770 |
Ref: Isolation and characterization of human anti-VEGF165 monoclonal antibody with anti-tumor efficacy from transgenic mice expressing human immunoglobulin loci. PMID: 18774636 Ref: Comparative study of human colonic tumor-derived endothelial cells (HCTEC) and normal colonic microvascular endothelial cells (HCMEC): Hypoxia-induced sVEGFR-1 and sVEGFR-2 levels. PMID: 19287991 Ref: Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. PMID: 19308410 Ref: No functional and transductional significance of specific neuropilin 1 siRNA inhibition in colon carcinoma cell lines lacking VEGF receptor 2. PMID: 19360289 Ref: Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. PMID: 19396600 Ref: The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. PMID: 19414323 Ref: Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. PMID: 19513949 Ref: Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474). PMID: 19528456 Ref: Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models. PMID: 19528458 Ref: Anti-angiogenic therapy against gastrointestinal tract cancers. PMID: 19531544 Ref: The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation. PMID: 19633424 Ref: [Monoclonal antibodies therapies for colorectal cancer: cetuximab, panitumumab and bevacizumab]. PMID: 19642458 Ref: VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo. PMID: 19707198 Ref: An overview of small-molecule inhibitors of VEGFR signaling. PMID: 19736552 Ref: Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. PMID: 19754219 Ref: Using dual-tracer PET to predict the biologic behavior of human colorectal cancer. PMID: 19837754 Ref: Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. PMID: 19876699 Ref: DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. PMID: 19946413 Ref: Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. PMID: 20072938 Ref: Quantitative analysis of vascular endothelial growth factor receptors 1 and 2 in colorectal cancer. PMID: 21475902 Ref: The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation. PMID: 28001118 |
Ref: Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial. PMID: 19396400 Ref: Heterogeneous expression of cyclooxygenase-2 and inducible nitric oxide synthase within colorectal tumors: correlation with tumor angiogenesis. PMID: 19497798 Ref: Minimally invasive colon resection for malignant colonic conditions is associated with a transient early increase in plasma sVEGFR1 and a decrease in sVEGFR2 levels after surgery. PMID: 19551437 Ref: K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRalpha in colorectal cancer. PMID: 19936766 Ref: Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. PMID: 20143086 Ref: Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. PMID: 20190562 Ref: Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer. PMID: 20222950 Ref: (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells. PMID: 20346928 Ref: Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). PMID: 20515975 Ref: Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells. PMID: 20599738 Ref: Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. PMID: 20606037 Ref: Antiangiogenic effect of licochalcone A. PMID: 20637733 Ref: Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. PMID: 20799147 Ref: Butyrate-rich colonic microenvironment is a relevant selection factor for metabolically adapted tumor cells. PMID: 20926374 Ref: Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. PMID: 20978198 Ref: Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives. PMID: 21028894 Ref: Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). PMID: 21036743 Ref: VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. PMID: 21098094 Ref: VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment. PMID: 21159176 Ref: Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6. PMID: 22966290 |
Ref: In vivo, dual-modality OCT/LIF imaging using a novel VEGF receptor-targeted NIR fluorescent probe in the AOM-treated mouse model. PMID: 21042865 Ref: Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. PMID: 21131552 Ref: GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. PMID: 21156786 Ref: Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. PMID: 21407219 Ref: The biflavonoid amentoflavone inhibits neovascularization preventing the activity of proangiogenic vascular endothelial growth factors. PMID: 21471210 Ref: Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer. PMID: 21498704 Ref: Pringle maneuver induces hepatic metastasis by stimulating the tumor vasculature. PMID: 21510298 Ref: Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. PMID: 21538846 Ref: Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. PMID: 21558395 Ref: Inhibition of VEGF induces cellular senescence in colorectal cancer cells. PMID: 21618508 Ref: SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. PMID: 21691074 Ref: Colorectal carcinoma cell production of transforming growth factor beta decreases expression of endothelial cell vascular endothelial growth factor receptor 2. PMID: 21692070 Ref: Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer. PMID: 21801343 Ref: The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience. PMID: 21868546 Ref: Pharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cells. PMID: 21919647 Ref: Bioactive properties and clinical safety of a novel milk protein peptide. PMID: 21943352 Ref: Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. PMID: 21964893 Ref: Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. PMID: 21976547 Ref: Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PMID: 22174910 Ref: Signaling pathways in hepatocellular carcinoma. PMID: 22212931 Ref: Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer. PMID: 22848274 |
Ref: Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2. PMID: 21658027 Ref: Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. PMID: 22065082 Ref: Angiogenesis in synchronous and metachronous colorectal liver metastases: the liver as a permissive soil. PMID: 22156924 Ref: Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. PMID: 22173549 Ref: Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer. PMID: 22182247 Ref: Zinc finger E-box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition. PMID: 22212097 Ref: A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. PMID: 22212406 Ref: Biomarkers for antitumor activity of bevacizumab in gastric cancer models. PMID: 22273502 Ref: Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects. PMID: 22273580 Ref: Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. PMID: 22363134 Ref: Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues. PMID: 22406047 Ref: Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. PMID: 22505231 Ref: Norcantharidin anti-angiogenesis activity possibly through an endothelial cell pathway in human colorectal cancer. PMID: 22524814 Ref: Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. PMID: 22617773 Ref: Adenovirus-mediated tissue-targeted expression of the CDglyTk gene for the treatment of breast cancer. PMID: 22641384 Ref: Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PMID: 22701615 Ref: Significant clinical response of advanced colon cancer to peptide vaccine therapy: a case report. PMID: 22763829 Ref: [Granzyme B-VEGF receptor-binding peptide fusion protein expressed in B. longum induces apoptosis of KDR-positive cells]. PMID: 22820600 Ref: Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. PMID: 22910317 Ref: Fast microbubble dwell-time based ultrasonic molecular imaging approach for quantification and monitoring of angiogenesis in cancer. PMID: 22943043 Ref: Astragalus saponins downregulate vascular endothelial growth factor under cobalt chloride-stimulated hypoxia in colon cancer cells. PMID: 22992293 Ref: A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation. PMID: 23059825 Ref: PDGFRalpha/beta and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome. PMID: 23146028 Ref: [Role of Ang-2, Tie-2 and VEGFR-2 in angiogenesis in colorectal carcinoma and their prognostic value]. PMID: 23174599 Ref: [Clinical study of Peptide-cocktail vaccination with tegafur-uracil/leucovorin for advanced colorectal cancer]. PMID: 23267878 |
Ref: Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. PMID: 22539090 Ref: Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). PMID: 22664478 Ref: CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth. PMID: 22935775 Ref: VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. PMID: 23108136 Ref: Association of VEGF and KDR single nucleotide polymorphisms with colorectal cancer susceptibility in Koreans. PMID: 23169005 Ref: Intratumoral FOXP3+VEGFR2+ regulatory T cells are predictive markers for recurrence and survival in patients with colorectal cancer. PMID: 23202541 Ref: Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer. PMID: 23314271 Ref: Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways. PMID: 23363445 Ref: Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor. PMID: 23435872 Ref: Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives. PMID: 23510598 Ref: The decrease of mineralcorticoid receptor drives angiogenic pathways in colorectal cancer. PMID: 23555666 Ref: Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. PMID: 23579861 Ref: YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models. PMID: 23594209 Ref: Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. PMID: 23603341 Ref: Critical appraisal of the use of regorafenib in the management of colorectal cancer. PMID: 23610528 Ref: Evaluation of (1)(8)F-FDG and (1)(8)F-FLT for monitoring therapeutic responses of colorectal cancer cells to radiotherapy. PMID: 23639776 Ref: Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells. PMID: 23651517 Ref: Angiogenin outperforms VEGF, EPCs and CECs in predicting Dukes' and AJCC stage in colorectal cancer. PMID: 23683169 Ref: Glucose-regulated protein 78 silencing down-regulates vascular endothelial growth factor/vascular endothelial growth factor receptor 2 pathway to suppress human colon cancer tumor growth. PMID: 23759331 Ref: Flt-1 in colorectal cancer cells is required for the tumor invasive effect of placental growth factor through a p38-MMP9 pathway. PMID: 23799978 Ref: Spica prunellae promotes cancer cell apoptosis, inhibits cell proliferation and tumor angiogenesis in a mouse model of colorectal cancer via suppression of stat3 pathway. PMID: 23800091 Ref: Clinical significance of VEGFR-2 and (1)(8)F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy. PMID: 23801169 Ref: S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. PMID: 23804704 Ref: Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways. PMID: 23843018 Ref: Inhibition of the angiogenesis and growth of Aloin in human colorectal cancer in vitro and in vivo. PMID: 23848964 Ref: Particled Mica, STB-HO has chemopreventive potential via G1 arrest, and inhibition of proliferation and vascular endothelial growth factor receptor 2 in HCT colorectal cancer cells. PMID: 23883349 Ref: Brucine suppresses colon cancer cells growth via mediating KDR signalling pathway. PMID: 23905676 Ref: VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer. PMID: 24083078 Ref: Anti-cancer activity of an osthole derivative, NBM-T-BMX-OS01: targeting vascular endothelial growth factor receptor signaling and angiogenesis. PMID: 24312323 Ref: [Treatment outcome of peptide vaccination for advanced colorectal cancer]. PMID: 24393856 Ref: Antitumor effect of FP3 on a patient-derived tumor tissue xenograft model of rectal carcinoma. PMID: 24719933 |
Ref: Synergic antitumor effect of SKLB1002 and local hyperthermia in 4T1 and CT26. PMID: 23263406 Ref: VEGFA, FLT1, KDR and colorectal cancer: assessment of disease risk, tumor molecular phenotype, and survival. PMID: 23794399 Ref: GDNF increases cell motility in human colon cancer through VEGF-VEGFR1 interaction. PMID: 24165321 Ref: Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. PMID: 24347491 Ref: Vascular progenitor clusters from peripheral blood in cancer patients following oncologic surgery. PMID: 24449173 Ref: Anti-tumor efficacy of ultrasonic cavitation is potentiated by concurrent delivery of anti-angiogenic drug in colon cancer. PMID: 24530229 Ref: Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin. PMID: 24531010 Ref: Wnt3a expression is associated with MMP-9 expression in primary tumor and metastatic site in recurrent or stage IV colorectal cancer. PMID: 24564183 Ref: Parthenolide exerts inhibitory effects on angiogenesis through the downregulation of VEGF/VEGFRs in colorectal cancer. PMID: 24573421 Ref: [New molecular targeting drugs for metastatic colorectal cancer]. PMID: 24597359 Ref: Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60. PMID: 24608894 Ref: A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. PMID: 24612787 Ref: Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings. PMID: 24625025 Ref: An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. PMID: 24674871 Ref: Brief report: impaired in vivo neovascularization capacity of endothelial progenitor cells in patients with systemic sclerosis. PMID: 24782187 Ref: Targeting angiogenic pathway for chemoprevention of experimental colon cancer using C-phycocyanin as cyclooxygenase-2 inhibitor. PMID: 24861078 Ref: SKLB-287, anovel oral multikinase inhibitor of EGFR and VEGFR2, exhibits potent antitumor activity in LoVo colorectal tumor model. PMID: 25030434 Ref: Quantum dots targeted to vascular endothelial growth factor receptor 2 as a contrast agent for the detection of colorectal cancer. PMID: 25104409 Ref: Dioscin inhibits colon tumor growth and tumor angiogenesis through regulating VEGFR2 and AKT/MAPK signaling pathways. PMID: 25111127 Ref: Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer. PMID: 25211664 Ref: [Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer]. PMID: 25335716 Ref: Inverse correlation of phospho-KDR/Flk-1 expression and stage of colorectal cancer: implication of the significance of neoangiogenesis in activated VEGFR-2 expressing early stage colorectal adenocarcinomas. PMID: 25372416 Ref: Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes. PMID: 25458604 Ref: Morpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth. PMID: 25534570 |
Ref: Soluble VEGFR1 concentration in the serum of patients with colorectal cancer. PMID: 24676933 Ref: Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. PMID: 25242168 Ref: Tissue-specific selection of optimal reference genes for expression analysis of anti-cancer drug-related genes in tumor samples using quantitative real-time RT-PCR. PMID: 25445497 Ref: Peroxiredoxin 2 is involved in vasculogenic mimicry formation by targeting VEGFR2 activation in colorectal cancer. PMID: 25471788 Ref: Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. PMID: 25532759 Ref: Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer. PMID: 25575176 Ref: Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. PMID: 25589620 Ref: Increased pre-surgical numbers of endothelial progenitor cells and circulating endothelial cells in colorectal cancer fail to predict outcome. PMID: 25598043 Ref: Raddeanin A, a triterpenoid saponin isolated from Anemone raddeana, suppresses the angiogenesis and growth of human colorectal tumor by inhibiting VEGFR2 signaling. PMID: 25636878 Ref: Pien Tze Huang Inhibits Hypoxia-Induced Angiogenesis via HIF-1 alpha /VEGF-A Pathway in Colorectal Cancer. PMID: 25649293 Ref: Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation. PMID: 25678082 Ref: Anticancer effect of salidroside on colon cancer through inhibiting JAK2/STAT3 signaling pathway. PMID: 25755753 Ref: 3-(Benzo[d][1,3]dioxol-5-ylamino)-N-(4-fluorophenyl)thiophene-2-carboxamide overcomes cancer chemoresistance via inhibition of angiogenesis and P-glycoprotein efflux pump activity. PMID: 25758415 Ref: A therapeutically relevant, 3,3'-diindolylmethane derivative NGD16 attenuates angiogenesis by targeting glucose regulated protein, 78kDa (GRP78). PMID: 25794856 Ref: VEGFR2 Signaling Prevents Colorectal Cancer Cell Senescence to Promote Tumorigenesis in Mice With Colitis. PMID: 25797700 Ref: Dopamine induces growth inhibition and vascular normalization through reprogramming M2-polarized macrophages in rat C6 glioma. PMID: 25818600 Ref: Human colon carcinogenesis is associated with increased interleukin-17-driven inflammatory responses. PMID: 25834404 Ref: A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. PMID: 25861837 Ref: Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. PMID: 25889309 Ref: The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab. PMID: 25926745 Ref: The relevance of cell type- and tumor zone-specific VEGFR-2 activation in locally advanced colon cancer. PMID: 25967108 Ref: VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments. PMID: 25980323 Ref: A Candidate-Pathway Approach to Identify Gene-Environment Interactions: Analyses of Colon Cancer Risk and Survival. PMID: 26072521 Ref: Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine. PMID: 26085010 Ref: Neuropilin-1 as Therapeutic Target for Malignant Melanoma. PMID: 26090340 Ref: Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells. PMID: 26107817 Ref: Widdrol, a sesquiterpene isolated from Juniperus chinensis, inhibits angiogenesis by targeting vascular endothelial growth factor receptor 2 signaling. PMID: 26133679 Ref: Morphological aspects of the hepatic response to neoadjuvant therapy. PMID: 26163186 Ref: Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia. PMID: 26206183 Ref: Wnt3a Promotes the Vasculogenic Mimicry Formation of Colon Cancer via Wnt/beta-Catenin Signaling. PMID: 26266404 Ref: Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis. PMID: 26325365 Ref: In vivo molecular imaging of colorectal cancer using quantum dots targeted to vascular endothelial growth factor receptor 2 and optical coherence tomography/laser-induced fluorescence dual-modality imaging. PMID: 26397238 Ref: [The anti-tumor activity and molecular mechanisms of an Aurora kinase inhibitor ZLJ213 in suppressing colon cancer growth]. PMID: 26552147 Ref: New active drugs for the treatment of advanced colorectal cancer. PMID: 26730280 |
Ref: RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. PMID: 26350096 Ref: Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells. PMID: 26419617 Ref: Comparison of (18)F-fluorodeoxyglucose PET/CT findings with vascular endothelial growth factors and receptors in colorectal cancer. PMID: 26476536 Ref: Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials. PMID: 26619847 Ref: Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? PMID: 26824184 Ref: Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. PMID: 26861740 Ref: Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors. PMID: 26887374 Ref: Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer. PMID: 26895445 Ref: High blood sugar levels significantly impact the prognosis of colorectal cancer patients through down-regulation of microRNA-16 by targeting Myb and VEGFR2. PMID: 26934556 Ref: Novel anti-angiogenic therapeutic strategies in colorectal cancer. PMID: 26938715 Ref: The safety of monoclonal antibodies for treatment of colorectal cancer. PMID: 26982510 Ref: KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer. PMID: 27004155 Ref: A novel kinase mutation in VEGFR-1 predisposes its alphaC-helix/activation loop towards allosteric activation: Atomic insights from protein simulation. PMID: 27049304 Ref: Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. PMID: 27099521 Ref: Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. PMID: 27117754 Ref: Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. PMID: 27149032 Ref: Genes, environment and gene expression in colon tissue: a pathway approach to determining functionality. PMID: 27186328 Ref: VEGFR2-Targeted Three-Dimensional Ultrasound Imaging Can Predict Responses to Antiangiogenic Therapy in Preclinical Models of Colon Cancer. PMID: 27206846 Ref: Copy number changes of clinically actionable genes in melanoma, non-small cell lung cancer and colorectal cancer-A survey across 822 routine diagnostic cases. PMID: 27218826 Ref: Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma. PMID: 27272777 Ref: Rifaximin, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway. PMID: 27279570 Ref: Synergistic inhibition of sunitinib and ethaselen against human colorectal cancer cells proliferation. PMID: 27372405 Ref: BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer. PMID: 27401244 Ref: A taspine derivative supresses Caco-2 cell growth by competitively targeting EphrinB2 and regulating its pathway. PMID: 27460008 Ref: A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab. PMID: 27462231 Ref: DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling. PMID: 27517319 Ref: Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing. PMID: 27568332 Ref: Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model. PMID: 27612418 Ref: Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers. PMID: 27651308 Ref: 4-isothiocyanate-2, 2, 6, 6-tetramethyl piperidinooxyl inhibits angiogenesis by suppressing VEGFR2 and Tie2 phosphorylation. PMID: 27698866 Ref: Effect of colorectal cancer on the number of normal stem cells circulating in peripheral blood. PMID: 27779706 Ref: Novel Sulfonamide Derivatives Carrying a Biologically Active 3,4-Dimethoxyphenyl Moiety as VEGFR-2 Inhibitors. PMID: 27904083 |
Ref: Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer. PMID: 27490690 Ref: Targeting acid sphingomyelinase with anti-angiogenic chemotherapy. PMID: 27702691 Ref: NHERF1 regulates the progression of colorectal cancer through the interplay with VEGFR2 pathway. PMID: 27999191 Ref: CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis. PMID: 28042950 Ref: Taspine derivative 12k suppressed A549 cell migration through the Wnt/beta-catenin and EphrinB2 signaling pathway. PMID: 28049091 Ref: Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation. PMID: 28060884 Ref: Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. PMID: 28138221 Ref: Design and Synthesis of Pyridazine Containing Compounds with Promising Anticancer Activity. PMID: 28250345 Ref: Validation of Bevacizumab Therapy Effect on Colon Cancer Subtypes by Using Whole Body Imaging in Mice. PMID: 28315202 Ref: Colorectal polypoid lesions and expression of vascular endothelial growth factor in a consecutive series of endoscopic and surgical patients. PMID: 28347226 Ref: Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. PMID: 28391576 Ref: Anti-VEGFR2-interferon-alpha2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer. PMID: 28405526 Ref: Secretion metabolites of probiotic yeast, Pichia kudriavzevii AS-12, induces apoptosis pathways in human colorectal cancer cell lines. PMID: 28477945 Ref: CPEB4 immunohistochemical expression is associated to prognosis in stage IV colorectal carcinoma. PMID: 28551384 Ref: Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1alpha and VEGF receptors. PMID: 28594907 Ref: The potential role of nintedanib in treating colorectal cancer. PMID: 28649871 Ref: Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. PMID: 28691930 Ref: Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion. PMID: 28742793 Ref: Catalpol suppressed proliferation, growth and invasion of CT26 colon cancer by inhibiting inflammation and tumor angiogenesis. PMID: 28826099 Ref: VEGFR2 regulates endothelial differentiation of colon cancer cells. PMID: 28854900 Ref: Potential Application of Eicosapentaenoic Acid Monoacylglyceride in the Management of Colorectal Cancer. PMID: 28869531 Ref: Targeting CXCR4-dependent immunosuppressive Ly6C(low) monocytes improves antiangiogenic therapy in colorectal cancer. PMID: 28900008 Ref: Sialyllactose suppresses angiogenesis by inhibiting VEGFR-2 activation, and tumor progression. PMID: 28938544 Ref: Multiple Gene-Environment Interactions on the Angiogenesis Gene-Pathway Impact Rectal Cancer Risk and Survival. PMID: 28956832 Ref: Prion Protein Family Contributes to Tumorigenesis via Multiple Pathways. PMID: 29052140 |
Ref: Synthesis, Characterization of 4-Anilino-6,7-Dimethoxy Quinazoline Derivatives as Potential Anti-Angiogenic Agents. PMID: 28403784 Ref: Assessing tumor angiogenesis in colorectal cancer by quantitative contrast-enhanced endoscopic ultrasound and molecular and immunohistochemical analysis. PMID: 28685747 Ref: The extracellular matrix protein mindin attenuates colon cancer progression by blocking angiogenesis via Egr-1-mediated regulation. PMID: 28991232 Ref: Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway. PMID: 29065844 Ref: The role of tumor angiogenesis as a therapeutic target in colorectal cancer. PMID: 29338550 Ref: IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides. PMID: 29498403 Ref: Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies. PMID: 29588308 Ref: Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. PMID: 29636300 Ref: Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology. PMID: 29740162 Ref: Association Between c-Met and Lymphangiogenic Factors in Patients With Colorectal Cancer. PMID: 29742856 Ref: Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing. PMID: 29844865 Ref: Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report. PMID: 29924031 Ref: Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. PMID: 29946728 Ref: ATAD2 silencing decreases VEGFA secretion through targeting has-miR-520a to inhibit angiogenesis in colorectal cancer. PMID: 29958090 Ref: Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice. PMID: 29977004 Ref: Cabozantinib exhibits potent antitumor activity in colorectal cancer patient-derived tumor xenograft models via autophagy and signaling mechanisms. PMID: 30026382 Ref: Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models. PMID: 30048249 Ref: The safety of ramucirumab for the treatment of colorectal cancer. PMID: 30073902 Ref: Synthesis, Computational Docking Study, and Biological Evaluation of a Library of Heterocyclic Curcuminoids with Remarkable Antitumor Activity. PMID: 30079563 Ref: Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway. PMID: 30151975 Ref: Light-enhanced VEGF121/rGel: A tumor targeted modality with vascular and immune-mediated efficacy. PMID: 30217739 Ref: [The impact of genetic variation of KDR on clinical outcomes of advanced colorectal cancer patients treated by first line bevacizumab based regimens]. PMID: 30220171 Ref: Pharmacokinetic Modeling of Targeted Ultrasound Contrast Agents for Quantitative Assessment of Anti-Angiogenic Therapy: a Longitudinal Case-Control Study in Colon Cancer. PMID: 30225758 Ref: Design, Synthesis and Biological Activity Evaluation of S-Substituted 1H-5-Mercapto-1,2,4-Triazole Derivatives as Antiproliferative Agents in Colorectal Cancer. PMID: 30234098 Ref: SP1-induced lncRNA-ZFAS1 contributes to colorectal cancer progression via the miR-150-5p/VEGFA axis. PMID: 30250022 Ref: Suppression of angiogenesis and tumor growth by recombinant T4 phages displaying extracellular domain of vascular endothelial growth factor receptor 2. PMID: 30259141 Ref: Oral Administration of Liposome-Apatinib and Locally Delivery of Docetaxel/MPEG-PCL by Fibrin Glue Synergistically Improve Therapeutic Effect in Colorectal Cancer. PMID: 30305215 |